Whales with a lot of money to spend have taken a noticeably bearish stance on Viking Therapeutics.
Looking at options history for Viking Therapeutics VKTX we detected 31 trades.
If we consider the specifics of each trade, it is accurate to state that 41% of the investors opened trades with bullish expectations and 58% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $185,077 and 28, calls, for a total amount of $2,866,768.
Expected Price Movements
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $3.0 to $135.0 for Viking Therapeutics over the last 3 months.
Insights into Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Viking Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Viking Therapeutics's substantial trades, within a strike price spectrum from $3.0 to $135.0 over the preceding 30 days.
Viking Therapeutics Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | TRADE | BEARISH | 01/17/25 | $10.00 | $601.5K | 4.1K | 0 |
| VKTX | CALL | TRADE | BULLISH | 09/20/24 | $55.00 | $269.7K | 168 | 0 |
| VKTX | CALL | SWEEP | BEARISH | 03/15/24 | $40.00 | $247.0K | 3.0K | 107 |
| VKTX | CALL | TRADE | BEARISH | 03/15/24 | $40.00 | $204.4K | 3.0K | 54 |
| VKTX | CALL | TRADE | BULLISH | 04/19/24 | $90.00 | $188.9K | 2 | 204 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
In light of the recent options history for Viking Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Current Position of Viking Therapeutics
- With a volume of 1,328,898, the price of VKTX is up 5.7% at $89.9.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 56 days.
Expert Opinions on Viking Therapeutics
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $81.2.
- An analyst from Maxim Group has decided to maintain their Buy rating on Viking Therapeutics, which currently sits at a price target of $50.
- Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Viking Therapeutics with a target price of $35.
- An analyst from Oppenheimer persists with their Outperform rating on Viking Therapeutics, maintaining a target price of $116.
- An analyst from Raymond James persists with their Outperform rating on Viking Therapeutics, maintaining a target price of $115.
- Consistent in their evaluation, an analyst from HC Wainwright & Co. keeps a Buy rating on Viking Therapeutics with a target price of $90.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
